

# Natural polymorphisms in HIV-1 CRF01\_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China

**Zesong Sun**

NHC Key Laboratory of AIDS Immunology (China Medical University)

**Jinming Ouyang**

NHC Key Laboratory of AIDS Immunology (China Medical University)

**Bin Zhao**

NHC Key Laboratory of AIDS Immunology (China Medical University)

**Minghui An**

NHC Key Laboratory of AIDS Immunology (China Medical University)

**Lin Wang**

NHC Key Laboratory of AIDS Immunology (China Medical University)

**Haibo Ding**

NHC Key Laboratory of AIDS Immunology (China Medical University)

**XiaoXu Han**

NHC Key Laboratory of AIDS Immunology (China Medical University)

**Hong Shang** (✉ [hongshang100@hotmail.com](mailto:hongshang100@hotmail.com))

NHC Key Laboratory of AIDS Immunology (China Medical University) <https://orcid.org/0000-0001-5333-8943>

---

## Research article

**Keywords:** HIV-1, CRF01\_AE, Polymorphism, Drug resistance mutation, Co-variation, Deep sequencing

**Posted Date:** September 14th, 2019

**DOI:** <https://doi.org/10.21203/rs.2.14340/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on February 26th, 2020. See the published version at <https://doi.org/10.1186/s12879-020-4808-3>.

# Abstract

**Background** The impacts of genetic polymorphisms on drug resistance mutations (DRMs) among various HIV-1 subtypes have long been debated. In this study, we aimed to analyze the natural polymorphisms and acquired DRM profile in HIV-1 CRF01\_AE-infected patients in a large Tenofovir/Lamivudine/Efavirenz (TDF/3TC/EFV) first-line antiretroviral therapy (ART) cohort in northeastern China.

**Methods** The natural polymorphisms of CRF01\_AE were analyzed in 2034 patients from a long-term ART cohort in northeastern China. The polymorphisms in 105 treatment failure (TF) patients were compared with those in 1148 treatment success (TS) patients. The acquired DRM profile of 42 patients who experienced TF with TDF/3TC/EFV treatment was analyzed by comparing the mutations at TF to those at baseline. The Stanford HIVdb algorithm was used to interpret the DRMs. Binomial distribution, McNemar test, and CorMut package were used to analyze the mutation rates and co-variation. Deep sequencing was used to analyze the evolutionary dynamics of co-variation.

**Results** Before ART, the natural polymorphisms of 31 sites on reverse transcriptase (RT) were significantly higher in CRF01\_AE than subtype B HIV-1 ( $|Z \text{ value}| \geq 3$ ), including five known drug resistance-associated sites (238, 118, 179, 103, and 40). However, only the polymorphism at site 75 was associated with TF ( $|Z \text{ value}| \geq 3$ ). The mutation rate at 14 sites increased significantly at TF compared to baseline, with the most common DRMs comprising G190S/C, K65R, K101E/N/Q, M184V/I, and V179D/I/A/T/E, ranging from 66.7% to 45.2%. Moreover, two unknown mutations (V75L and L228R) increased by 19.0% and 11.9% respectively, and they were under positive selection ( $K_a/K_s > 1$ , log odds ratio [LOD]  $> 2$ ) and were associated with several other DRMs ( $cK_a/K_s > 1$ , LOD  $> 2$ ). Deep sequencing of longitudinal plasma samples showed that L228R occurred simultaneously or followed the appearance of Y181C.

**Conclusion** The high levels of polymorphisms in CRF01\_AE had little impact on treatment outcomes. The findings regarding potential new CRF01\_AE-specific minor DRMs indicate the need for more studies on the drug resistance phenotype of CRF01\_AE.

## Background

At the end of 2017, there were approximately 36.9 million people living with HIV, 59% of whom were receiving antiretroviral therapy (ART) [1], which significantly reduces morbidity and mortality but requires lifelong treatment. Moreover, some people experience treatment failure (TF) because of drug resistance [2]. A multicenter retrospective cohort study of 1926 patients who failed first-line regimens from 36 countries between 1998 to 2015 showed that the drug resistance rate at TF was 20–35% in Europe and North America and up to 57% in sub-Saharan Africa [3]. Drug-resistant strains can also spread to treatment-naïve patients, causing HIV transmitted drug resistance (TDR) [4]. A study of 4140 treatment-naïve newly diagnosed HIV-infected individuals from 26 European countries between 2008 and 2010 showed that the overall prevalence of TDR was 8.3% and it did not change significantly over time [5].

However, it is increasing at a substantial rate in low- and middle-income countries (LMICs). This is especially true regarding the resistance rate to non-nucleoside reverse transcriptase inhibitors (NNRTIs), which was near 10% in southern and eastern Africa and Latin America in 2016, the threshold used by the World Health Organization (WHO) to determine when to change first-line ART regimens [6].

Most drug resistance genotype data are derived from subtype B of HIV-1, which is responsible for about 12% of infections worldwide and is mainly epidemic in North America and Europe [7]. However, non-B HIV-1 strains demonstrate many genetic differences from subtype B, and this might enable different types and rates of drug resistance mutations (DRMs) to the same drugs [8–10]. Both in vitro and in vivo studies have shown inconsistencies in DRMs between subtype B and some non-B HIV-1 strains [11, 12]. For example, V90I and V179E occurred more frequently after treatment with etravirine (ETR) and rilpivirine (RPV) in non-B HIV-1 compared to subtype B HIV-1 [13]. It has been suggested that the Stanford HIVdb algorithm derived from subtype B HIV-1 might not be completely applicable to non-B HIV-1, and more studies are needed on the genetic polymorphisms and DRM characteristics of non-B HIV-1 strains.

CRF01\_AE is the first reported circulating recombinant form (CRF) of HIV-1 and one of the most influential CRFs in the world [14], accounting for 5.3% of the total HIV-1 infections worldwide and increasing over time [7]. CRF01\_AE accounts for about 80% of CRFs in southeast and east Asia, and it increased consistently in east Asia between 2010 to 2015 [7]. In China, CRF01\_AE is one of the main epidemic strains of HIV-1, accounting for 42.5% of the reported HIV-1 infection cases in China according to a systematic review [15].

The DRM characteristics of CRF01\_AE have been reported in several cross-sectional studies. However, most of these population-based studies assessed the prevalence of transmitted or acquired DRMs among populations [16–19] or compared the mutation rates between different populations [20, 21]. Few studies have evaluated the associations between polymorphisms and treatment outcomes. Even fewer studies have performed self-control analyses in ART cohorts and evaluations of the correlations between various mutations.

In this study, we analyzed the natural polymorphisms of CRF01\_AE from a large ART cohort in northeastern China and compared the polymorphisms between patients who experienced TF and those who experienced treatment success (TS). The acquired DRM profile was determined using self-control analyses that involved comparing baseline data to data collected at TF. Moreover, the potential role of unknown mutations was explored through co-variation analysis and next-generation sequencing (NGS).

## Materials And Methods

### *Study design and participants*

2034 HIV-1 CRF01\_AE-infected patients were selected from a long-term ART cohort at the First Affiliated Hospital, China Medical University in Shenyang between January 2002 and December 2017. Partial HIV-1 *pol* sequences (HXB2: 2253–3269) obtained during genotypic drug resistance testing for each

participant at baseline were used to analyze the natural polymorphisms of CRF01\_AE. 1330 patients received ART, of which 105 experienced TF according to the following inclusion criteria: 1) treatment for at least 6 months, 2) persistently detectable viral load >1000 copies/ml [22], and 3) DRMs were detected. Forty-two TF patients receiving Tenofovir/Lamivudine/Efavirenz (TDF/3TC/EFV) treatment, the first-line regimen in China, were further selected to analyze the acquired DRM profile of CRF01\_AE. The study was approved by the Ethics Committee of the First Affiliated Hospital of China Medical University and all patients signed informed consent forms. The flow chart of participant selection and analysis is shown in *Additional file 1 (Figure S1)*. Data on the demographic and clinical characteristics of all participants were collected from clinical records and are shown in *Additional file 2*.

## Phylogenetic and genotypic resistance analyses

For phylogenetic analysis, the *pol* sequences obtained during genotypic drug resistance testing for each 2034 CRF01\_AE-infected patient at baseline were aligned with the reference sequences from the Los Alamos HIV database (<https://www.hiv.lanl.gov/>), and phylogenetic trees were then constructed by the maximum likelihood method using FastTree1.3.1 software. DRMs were identified using the Stanford University HIV Drug Resistance Database (<https://hivdb.stanford.edu/>) and interpreted using the Stanford HIVdb algorithm (<https://hivdb.stanford.edu/hivdb/by-mutations/>).

## Polymorphism analysis

The mutation rates of amino acids at sites 1 to 240 of reverse transcriptase (RT) region of the *pol* gene were compared between the 2034 treatment-naïve CRF01\_AE sequences and subtype B sequences from treatment-naïve patients in the Stanford University HIV Drug Resistance Database, with an average of 46118 sequences per site (<https://hivdb.stanford.edu/cgi-bin/RTMutSummary.cgi>). The mutation rates were also compared between 1148 TS patients and 105 TF patients. The HIV-1 strain HXB2 was used as the reference standard. The sites with a different amino acid (compared to the corresponding site in HXB2), and with a prevalence >1%, were defined as natural polymorphism sites.

## Co-variation analysis

The CorMut package [23] (version 1.25.0) based on the R Project for Statistical Analysis (R version 3.5.2) was used to analyze co-variation. The HIV-1 strain HXB2 was used as the reference sequence. Positively selected mutations (PSMs) were determined using selection pressure (Ka/Ks ratio), with Ka/Ks >1 and log odds ratio (LOD)>2 [24]. Conditional selection pressure (conditional Ka/Ks, cKa/Ks) was used to measure the correlation between PSMs, with cKa/Ks>1 and LOD>2 indicating the presence of directional co-variation.

## Temporal analysis of Y181C/ L228R mutations by deep sequencing

Longitudinal plasma samples between baseline and TF from four cases with Y181C and L228R mutations were selected. Viral RNA was extracted from the plasma samples using a QIAmp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol and reverse transcribed using a Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Indianapolis, IN, USA) with the specific primer Rev2-1 (5'-TCCTGCCATRGRAGATGCCTAA-3'). A 453-bp fragment (HXB2: 2868-3320) in the RT region of the *pol* gene was then amplified by two rounds of nested polymerase chain reaction (PCR) using a KOD-Plus-Neo kit (TOYOBO, Osaka, Japan) with the following outer and inner primers, respectively: MAW26/RT-21n (5'-GTATTTCTGCATTAAGTCTTTTGGATGG-3'), 3-3F (5'-ACAGTACTAGATGTGGGAGATGC-3')/3-3R (5'-TATATCATTGACAGTCCAGCTGTC-3'). The reaction conditions are shown in *Additional file 3*.

The PCR products were purified with Agencourt AMPure XP beads (Beckman Coulter, Brea, CA, USA) and then quantified using a Qubit 3.0 Fluorometer (Life Technologies, Carlsbad, CA, USA). The fragment length was accurately evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). Subsequently, the purified PCR products were adjusted to 2.5 ng/μl and indexed with an adaptor using a TruSeq Nano DNA LT library preparation kit (Illumina, San Diego, CA, USA) according to the manufacturer's protocol. The indexed DNA libraries were analyzed using the Agilent 2100 Bioanalyzer and accurately quantified using a Roche LightCycler® 480 (LC480) Real-Time PCR system (Roche, Risch, Switzerland) and normalized to 10 nM, then pooled, denatured, and diluted to 15 pM, and finally mixed with 50% PHIX Control Libraries (Illumina, San Diego, CA, USA) to create a final volume of 600 μl.

Deep sequencing was performed using an Illumina MiSeq System (Illumina, San Diego, CA, USA). The sequencing quality was evaluated using FASTQC software (version 0.11.7). In the virtual environment constructed by Virtual Box-5.2.22, QIIME2 and DADA2 software (<http://qiime.org/>) were used to perform bioinformatics processing on the generated paired-end FASTQ sequence files and then to statistically analyze the mutation types and rates at the target amino acid sites in each sample.

## Statistical analysis

The mutation rate of each amino acid site of RT was compared between treatment-naïve CRF01\_AE and subtype B, between TS and TF CRF01\_AE-infected patients, and between baseline and TF in 42 TF patients using the binomial distribution. The mutation rates of the 42 CRF01\_AE TF patients between baseline and TF were also compared using McNemar test. The statistical calculations were performed using SPSS software (version 20.0).  $P < 0.05$  was used as the cutoff for significance.

## Results

### *Transmitted drug resistance mutations and natural polymorphisms of CRF01\_AE virus before treatment*

In this study, 41 out of 2034 (2.02%) treatment-naïve CRF01\_AE-infected patients had transmitted DRMs, with the common DRMs comprising K103N, G190S, K101E, T215S, K65R, and K219Q. In addition to these

mutations, natural polymorphisms of amino acids with a prevalence >1% were detected at 53 (53/240, 22.1%) sites in RT, of which nine sites (40, 68, 69, 98, 103, 118, 179, 210, and 238) were known drug resistance-associated sites. Compared with global subtype B strains in the Stanford HIV Drug Resistance Database (<https://hivdb.stanford.edu/cgi-bin/RTMutSummary.cgi>), 31 sites (4, 5, 6, 8, 11, 28, 32, 35, 36, 39, 40, 43, 88, 103, 104, 105, 111, 118, 123, 135, 172, 173, 174, 177, 179, 200, 203, 207, 211, 214, and 238) in CRF01\_AE had higher mutation rates ( $|Z \text{ value}| \geq 3$ ) (*Fig. 1*). These sites were defined as CRF01\_AE-specific polymorphism sites, which included five known drug resistance-associated sites, site 238 (73.8%), site 118 (26.1%), site 179 (21.2%), site 103 (8.1%), and site 40 (3.1%), and 26 other sites that were not known to be associated with drug resistance (*Fig. 1*).

As multiple lineages of CRF01\_AE have been reported in China, we further analyzed the potential differences in natural polymorphisms between various lineages. According to the phylogenetic analysis, the 2034 sequences mainly belonged to two lineages, including 416 (20.5%) sequences belonging to lineage 1, 1522 (74.8%) sequences belonging to lineage 2, and another 96 (4.7%) sequences belonging to other CRF01\_AE lineages (Additional file 4: *Figure S2*). Fifty-one and forty-four natural polymorphism sites in lineages 1 and 2 were detected, respectively, with differences in 35 sites between the two lineages ( $|Z \text{ value}| \geq 3$ ). Both lineages had 26 polymorphism sites with higher mutation rates than in subtype B HIV-1 ( $|Z \text{ value}| \geq 3$ ), including two known drug resistance-associated sites (sites 179 and 238) (*Fig. 1*).

## Natural polymorphisms of CRF01\_AE had little impact on treatment outcomes

A total of 1330 out of 2034 CRF01\_AE-infected patients received first-line ART (two nucleoside reverse transcriptase inhibitors [NRTIs] + one NNRTI), among which 105 (7.9%) patients experienced TF. We found 13 sites with differences between TF and TS patients (1148, 86.3%), comprising the polymorphisms at sites 75 and 189, which were only found in TF patients, and the polymorphisms at sites 4, 5, 8, 21, 32, 49, 105, 165, 169, 171, and 204, which were only found in the TS patients. The mutation rate of site 75 in TF patients was significantly higher than in TS patients ( $|Z \text{ value}| \geq 3$ ) (*Fig. 2*).

## Common DRMs and potential new DRMs developed in CRF01\_AE-infected patients with TDF/3TC/EFV TF

To determine the acquired DRM profile of CRF01\_AE, 42 CRF01\_AE-infected patients with TDF/3TC/EFV TF were selected. The mutation rates of 14 sites increased significantly at TF, with rates ranging from 9.5% to 66.7% (*Table 1*). Of these 14 sites, 13 were known drug resistance-associated sites, including seven NRTI-associated sites and six NNRTI-associated sites. The NRTI-associated DRMs detected at TF in descending order included K65R (57.1%), M184V/I (47.6%), S68G (26.2%), A62V (23.8%), K70/E/R (9.5%), and Y115F (9.5%). The NNRTI-associated DRMs detected at TF included G190S/C (66.7%), K101E/N/Q (52.4%), V179D/I/A/T/E (45.2%), Y181C (42.9%), K103R/N/S (42.9%), and V106M (23.8%) (*Table 1*). It was noted that an unknown mutation (V75L) was detected at site 75, a drug resistance-associated site,

which increased from 4.8% at baseline to 16.7% at TF (Z value = 2.494,  $p < 0.05$ ;  $p_{\text{McNemar test}} = 0.008$ ). Moreover, a new mutation (L228R) was detected at site 228, a non-DRM site in the Stanford HIVdb algorithm, which increased from 0% at baseline to 11.9% at TF (Z value = 2.306,  $p < 0.05$ ;  $p_{\text{McNemar test}} = 0.063$ ). We speculated that both V75L and L228R might be potential new DRMs in CRF01\_AE.

### *Relationships of potential new DRMs with known DRMs*

To explore the role of potential new DRMs, the mutations at 14 sites with significantly increased mutation rates at TF were used for co-variation analyses. Nine known DRMs (K65R, V106M, Y115F, V179T/E/D, Y181C, M184V, and G190S) and two potential new DRMs (V75L and L228R) were demonstrated to be under positive selection pressure ( $K_a/K_s > 1$ ,  $\text{LOD} > 2$ ). 28 links were detected among these mutations ( $cK_a/K_s > 1$ ,  $\text{LOD} > 2$ ) (Table 2).. Among them, the known DRMs Y181C and G190S showed the strongest correlation ( $cK_a/K_{s_{Y181C-G190S}} = 22.86$ ,  $\text{LOD} = \text{infinity}$ ). V75L was correlated with known DRMs G190S ( $cK_a/K_{s_{V75L-G190S}} = 3.24$ ,  $\text{LOD} = \text{infinity}$ ), K65R ( $cK_a/K_{s_{K65R-V75L}} = 2.00$ ,  $\text{LOD} = 5.04$ ), and M184V ( $cK_a/K_{s_{V75L-M184V}} = 1.25$ ,  $\text{LOD} = 4.03$ ). L228R was correlated with known DRMs G190S ( $cK_a/K_{s_{L228R-G190S}} = 2.25$ ,  $\text{LOD} = \text{infinity}$ ), K65R ( $cK_a/K_{s_{K65R-L228R}} = 2.00$ ,  $\text{LOD} = 3.46$ ), and strongly correlated with Y181C ( $cK_a/K_{s_{Y181C-L228R}} = 6.00$ ,  $\text{LOD} = 4.09$ ) (Table 2)..

## **L228R occurred simultaneously or followed the appearance of Y181C**

To further explore the temporal association and the evolutionary dynamics between Y181C and L228R, longitudinal plasma samples of four CRF01\_AE-infected patients with Y181C and L228R mutations were studied using deep sequencing. The first case demonstrated a time lag between the Y181C and L228R mutations; Y181C occurred in 53.4% of the sequences at 1 month post treatment, which increased to 100% at 3 months post treatment, and L228R did not appear until 6 months post treatment, when 87.1% of sequences carried both Y181C and L228R mutations. The second and third cases had Y181C and L228R only at TF. For one of these cases, 100% of sequences carried both Y181C and L228R simultaneously while, for the other case, 80% of sequences carried both Y181C and L228R simultaneously, and the remaining 20% carried only Y181C (Fig.3).. The fourth case could not be analyzed due to sequencing failure.

## **Discussion**

To our knowledge, this study provides the most comprehensive information on HIV-1 drug resistance-associated natural polymorphisms and the acquired DRM profile of CRF01\_AE in China to date using a large dataset from a long-term ART cohort in Shenyang. CRF01\_AE isolates in this study demonstrated high levels of polymorphisms at both DRM sites and other sites, with several lineage-specific characteristics. However, the little variation in polymorphisms between TF and TS patients implied little impact of CRF01\_AE polymorphisms on the development of DRMs. Moreover, this study found that the most common NRTIs and NNRTIs-associated DRMs among CRF01\_AE patients who experienced TF were

similar to those DRMs among subtype B patients. However, several potential new DRMs selected during ART might be CRF01\_AE-specific DRMs. Among these DRMs, L228R occurred simultaneously or following the appearance of Y181C, and it might be an accessory mutation to Y181C.

In this study, 31 CRF01\_AE-specific polymorphism sites (including five known DRMs) were detected, which is even higher than the number of polymorphism sites in CRF01\_AE strains mainly from Southeast Asia in a global study on non-B HIV-1 over 10 years ago [25]. Moreover, the two CRF01\_AE lineages in this study corresponded to the two lineages epidemic mainly among men who have sex with men (MSM) in China [26, 27], and they demonstrated both common and lineage-specific polymorphisms. A similar situation also occurred for gag and env regions of different lineages of CRF01\_AE [28], suggesting that other lineages of CRF01\_AE in China might have distinct polymorphisms, which might further complicate DRM development and drug resistance genotype interpretation [29].

In this study, the polymorphisms at five known drug resistance-associated sites (V179I/D, V118I, K103R, K238R, and E40Q) were polymorphic accessory mutations or other mutations that did not independently decrease drug sensitivity. None of them were associated with TF. Only V75L, a low-frequency mutation, was associated with virologic failure, implying that most polymorphisms in CRF01\_AE seldom lead to TF. A study from a London cohort found that different baseline polymorphisms, including V90I, A98S, and K103R, were associated with virologic failure [30], but their effects could not be differentiated from the impacts of the different treatment regimens and HIV strains.

At present, two NRTIs plus an integrase strand transfer inhibitor (INSTI) are recommended as a first-line ART regimen for adults in developed countries while, in developing countries like China, two NRTIs plus an NNRTI are still recommended as a first-line ART regimen. In this study, we evaluated the DRM profile of CRF01\_AE after TDF/3TC/EFV TF. The most common acquired DRMs among CRF01\_AE were K65R, M184V, G190S/C, Y181C, and K103R, all of which are also common among subtype B and other subtypes. Despite some differences in the mutation type and rate, we cannot confirm that the differences were caused by the various subtypes [31, 32].

More importantly, we detected two mutations with significant increases but without annotation in the Stanford HIVdb algorithm, V75L and L228R. Site 75 is a drug resistance-associated site but no explanation for V75L is provided in the Stanford HIVdb algorithm. The V75L mutation has been reported to provide a selective advantage by allowing escape from the host immune responses [33] and it is believed to be a TDF-associated mutation [21]. The L228R mutation has been reported to be related to the treatment of non-B HIV-1 subtypes in several studies [34, 35], and its phenotype has not yet been described. In this study, for the first time, it was suggested that L228R might be associated with the known DRM Y181C and it might act as an accessory mutation to Y181C based on a co-variation analysis and longitudinal evolution study. These results implied that more unannotated mutations in non-B HIV-1 during TF might be accessory mutations associated with drug resistance. Therefore, more studies are needed to strengthen the phenotypic research on drug resistance in non-B HIV-1 [36], and to provide more evidence for drug resistance interpretation for non-B HIV-1.

Several limitations exist in the present study. First, due to the high success rate of ART in this cohort, only a small number of TF patients could be included in the acquired DRM analysis. Second, the impact of the L228R mutation with or without Y181C needs further validation using virus growth competition and drug resistance phenotype assays. Nevertheless, this study provided more evidence of polymorphisms and DRMs in the non-B HIV-1 strain CRF01\_AE.

## Conclusions

In summary, the high levels of polymorphisms in CRF01\_AE had little impact on treatment outcomes, but some unknown mutations associated with TF might be minor DRMs. The results of this study indicate the need for more studies on drug resistance in non-B HIV-1, especially phenotypic studies to strengthen the drug resistance genotype interpretation, and to improve ART efficacy and minimize the transmission of drug-resistant strains.

## Declarations

### Additional files

Additional file 1: Figure S1. Flow chart of participant selection and analysis. (PDF 13 kb)

Additional file 2: Demographic and clinical characteristics of participants in this study. (PDF 79 kb)

Additional file 3: Reaction conditions of cDNA synthesis and amplification of the target fragment. (PDF 43 kb)

Additional file 4: Figure S2. Phylogenetic tree analyses of the HIV-1 CRF01\_AE *pol* sequences. (PDF 625 kb)

## Abbreviations

ART: Antiretroviral therapy; CRF: Circulating recombinant form; DRMs: Drug resistance mutations; ETR: Etravirine; INSTI: Integrase strand transfer inhibitor; LMICs: Low-and middle-income countries; LOD: Log odds ratio; MSM: Men who have sex with men; NGS: Next-generation sequencing; NNRTIs: Non-nucleoside reverse transcriptase inhibitors; NRTIs: Nucleoside reverse transcriptase inhibitors; PCR: Polymerase chain reaction; PSMs: Positively selected mutations; RPV: Rilpivirine; RT: Reverse transcriptase; TDF/3TC/EFV: Tenofovir/Lamivudine/Efavirenz; TDR: Transmitted drug resistance; TF: Treatment failure; TS: Treatment success; WHO: World Health Organization.

## Acknowledgements

We are grateful for the collaboration of the patients, medical and nursing staff, and data managers in this study. We wish to thank Prof. Feng Gao of Duke University for the constructive discussion on the design of this study. We would also like to thank The Charlesworth Group for English language editing.

## **Funding**

This study was supported by The Mega-projects of National Science Research for the 13th Five-Year Plan (2017ZX10201101), the Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences (2018PT31042), and the National Natural Science Foundation (81871637). The funding bodies had no role in the design of the study, the collection, analysis, or interpretation of the data, or writing the manuscript.

## **Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## **Authors' contributions**

SZS, OYJM and HXX wrote and revised the manuscript with support from SH. HXX designed the study. ZB, AMH, and DHB provided the demographic and clinical characteristics data and the drug resistance monitoring data. WL guided the experimental operations, and SZS and OYJM performed the experiments and data analysis. All authors read and approved the final manuscript.

## **Ethics approval and consent to participate**

The study was approved by the Ethics Committee of the First Affiliated Hospital of China Medical University and all subjects provided written informed consent.

## **Consent for publication**

Not applicable.

## **Competing interests**

The authors declare that there are no competing interests associated with this study.

## **Author details**

<sup>1</sup> NHC Key Laboratory of AIDS Immunology (China Medical University), Department of Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.

<sup>2</sup> National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.

<sup>3</sup> Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, 110001, China.

<sup>4</sup> Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, 79 Qingchun Street, Hangzhou, 310003, China.

<sup>5</sup> Department of Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.

## References

1. World Health Organization. HIV/AIDS-Key facts [Internet]. Available at [<https://www.who.int/en/news-room/fact-sheets/detail/hiv-aids>]. Accessed in 07/19/2018.
2. Menéndez-Arias L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. *Antiviral Res.* 2013;98:93–120.
3. TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV–1 infection: a multicentre retrospective cohort study. *The Lancet Infectious diseases.* 2016;16:565–75.
4. Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV–1 drug resistance and resistance testing. Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2016;46:292–307.
5. Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC et al. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. *Clin Infect Dis.* 2016;62:655–63.
6. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, Kaleebu P et al. HIV–1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. *The Lancet Infectious diseases.* 2018;18:346–55.
7. Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, Williams B et al. Global and regional molecular epidemiology of HIV–1, 1990–2015: a systematic review, global survey, and trend analysis. *The Lancet Infectious diseases.* 2019;19:143–55.
8. Ariën KK, Abraha A, Quiñones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV–1) group M, HIV–1 group O, and HIV–2 isolates. *J Virol.* 2005;79:8979–90.

9. Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, Tebit DM et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. *PLoS Pathog.* 2009;5:e1000365.
10. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. *Science (New York, NY).* 1996;271:1582-6.
11. Yang J, Geng W, Zhang M, Han X, Shang H. Discordance between genotypic resistance and pseudovirus phenotypic resistance in AIDS patients after long-term antiretroviral therapy and virological failure. *J Basic Microbiol.* 2014;54:1120-5.
12. Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S, De Oliveira T, Pillay D et al. Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. *Antimicrob Agents Chemother.* 2015;59:960-71.
13. Anta L, Blanco JL, Llibre JM, García F, Pérez-Elías MJ, Aguilera A, Pérez-Romero P et al. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. *The Journal of antimicrobial chemotherapy.* 2013;68:1994-2002.
14. Gao F, Robertson DL, Morrison SG, Hui H, Craig S, Decker J, Fultz PN et al. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. *J Virol.* 1996;70:7013-29.
15. Li X, Li W, Zhong P, Fang K, Zhu K, Musa TH, Song Y et al. Nationwide Trends in Molecular Epidemiology of HIV-1 in China. *AIDS Res Hum Retroviruses.* 2016;32:851-9.
16. Li J, Xu Y, Liu J, Yang B, Yang C, Zhang M, Dong X. Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China. *Virol J.* 2019;16:5.
17. Yendewa GA, Sahr F, Lakoh S, Ruiz M, Patiño L, Tabernilla A, Deen GF et al. Prevalence of drug resistance mutations among ART-naïve and -experienced HIV-infected patients in Sierra Leone. *The Journal of antimicrobial chemotherapy.* 2019;74:2024-9.
18. Jiao Y, Li S, Li Z, Zhang Z, Zhao J, Li L, Wang L et al. HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China. *BMC Infect Dis.* 2014;14:689.
19. Poon AFY, Ndashimye E, Avino M, Gibson R, Kityo C, Kyeyune F, Nankya I et al. First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda. *AIDS Res Ther.* 2019;16:3.
20. Saeng-aroon S, Tsuchiya N, Auwanit W, Ayuthaya PI, Pathipvanich P, Sawanpanyalert P, Rojanawiwat A et al. Drug-resistant mutation patterns in CRF01\_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort. *Antiviral Res.* 2010;87:22-9.
21. Rhee SY, Varghese V, Holmes SP, Van Zyl GU, Steegen K, Boyd MA, Cooper DA et al. Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing

- First-Line Regimen: An International Collaboration. *EBioMedicine*. 2017;18:225–35.
22. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach.; June 2013.
  23. Li Z, Huang Y, Ouyang Y, Jiao Y, Xing H, Liao L, Jiang S et al. CorMut: an R/Bioconductor package for computing correlated mutations based on selection pressure. *Bioinformatics* (Oxford, England). 2014;30:2073–5.
  24. Liu P, Feng Y, Wu J, Tian S, Su B, Wang Z, Liao L et al. Polymorphisms and Mutational Covariation Associated with Death in a Prospective Cohort of HIV/AIDS Patients Receiving Long-Term ART in China. *PLoS One*. 2017;12:e0170139.
  25. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J et al. Impact of HIV–1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. *PLoS Med*. 2005;2:e112.
  26. An M, Han X, Xu J, Chu Z, Jia M, Wu H, Lu L et al. Reconstituting the epidemic history of HIV strain CRF01\_AE among men who have sex with men (MSM) in Liaoning, northeastern China: implications for the expanding epidemic among MSM in China. *J Virol*. 2012;86:12402–6.
  27. Feng Y, He X, Hsi JH, Li F, Li X, Wang Q, Ruan Y et al. The rapidly expanding CRF01\_AE epidemic in China is driven by multiple lineages of HIV–1 viruses introduced in the 1990s. *AIDS* (London, England). 2013;27:1793–802.
  28. Cheng CL, Feng Y, He X, Lin P, Liang SJ, Yi ZQ, He JM et al. Genetic characteristics of HIV–1 CRF01\_AE strains in four provinces, southern China. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2009;30:720–5.
  29. Langs-Barlow A, Paintsil E. Impact of human immunodeficiency virus type–1 sequence diversity on antiretroviral therapy outcomes. *Viruses*. 2014;6:3855–72.
  30. Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P et al. The impact of HIV–1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV–1-infected adults. *AIDS* (London, England). 2013;27:2245–53.
  31. Turner D, Shahar E, Katchman E, Kedem E, Matus N, Katzir M, Hassoun G et al. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV–1 subtypes in Israel. *J Med Virol*. 2009;81:1509–12.
  32. Sunpath H, Wu B, Gordon M, Hampton J, Johnson B, Moosa MY, Ordonez C et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. *AIDS* (London, England). 2012;26:1679–84.
  33. Shao W, Kearney M, Maldarelli F, Mellors JW, Stephens RM, Lifson JD, KewalRamani VN et al. RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy. *Retrovirology*. 2009;6:101.
  34. Huang Y, Li Z, Xing H, Jiao Y, Ouyang Y, Liao L, Jiang S et al. Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV–1 CRF\_BC strains. *PLoS One*. 2014;9:e93804.

35. Monno L, Scudeller L, Brindicci G, Saracino A, Punzi G, Chirianni A, Lagioia A et al. Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects. *Antiviral Res.* 2009;83:118–26.
36. A. Jiamsakul, R. Chaiwarith, N. Durier, S. Sirivichayakul, S. Kiertiburanakul, P. Van Den Eede, R. Ditangco et al. Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01\_AE and subtype B HIV-infected individuals. *J Med Virol.* 2016;88:234–43.

## Tables

**Table 1.** Increase of mutation types and rates associated with failure of first-line treatment for HIV-1 CRF01\_AE

WT	B-WT	Mutations	Mutation rate (%)		Binomial distribution		McNemar test	
			Baseline	TF	Increase (%)	Z value	p	p
A	V		0	14.3	14.3	2.542	<b>&lt;0.05</b>	<b>0.031</b>
K	R		0	57.1	57.1	5.797	<b>&lt;0.05</b>	<b>&lt;0.001</b>
S	G		4.8	26.2	21.4	2.715	<b>&lt;0.05</b>	<b>0.004</b>
K	E	R	0	9.5	9.5	2.049	<b>&lt;0.05</b>	0.125
V	L	I	4.8	23.8	19.0	2.494	<b>&lt;0.05</b>	<b>0.008</b>
K	E	Q	0	52.4	52.4	5.460	<b>&lt;0.05</b>	<b>&lt;0.001</b>
K	R	N	21.4	42.9	21.5	2.103	<b>&lt;0.05</b>	<b>0.004</b>
V	M		2.4	23.8	21.4	2.911	<b>&lt;0.05</b>	<b>0.012</b>
Y	F		0	9.5	9.5	2.049	<b>&lt;0.05</b>	0.125
V	D	I	26.2	45.2	19.0	1.822	>0.05	<b>0.008</b>
Y	C		0	42.9	42.9	4.786	<b>&lt;0.05</b>	<b>&lt;0.001</b>
M	V	I	0	47.6	47.6	5.123	<b>&lt;0.05</b>	<b>&lt;0.001</b>
G	S	C	0	66.7	66.7	6.481	<b>&lt;0.05</b>	<b>&lt;0.001</b>
L	R		0	11.9	11.9	2.306	<b>&lt;0.05</b>	0.063


B-WT, subtype B wild type. TF, treatment failure. Boldface P values indicate  $P < 0.05$ . The boldface sites are known drug resistance-associated sites. The mutations listed are the types of mutations that occur at TF.

**Table 2.** Co-variations of conditional selection pressure (cKa/Ks)

Mut1	Mut2	cKa/Ks	LOD	Mut1	Mut2	cKa/Ks	LOD
Y181C	G190S	22.86	Inf	K65R	Y115F	2	3.93
G190S	K65R	18	10.69	K65R	V179T	2	Inf
G190S	Y181C	17	10.06	K65R	V179E	2	Inf
Y181C	<b>L228R</b>	6	4.09	K65R	<b>L228R</b>	2	3.46
V179D	V106M	5	Inf	M184V	Y115F	2	3.93
K65R	G190S	3.97	Inf	M184V	V179D	2	9.16
K65R	Y181C	3.5	7.73	Y181C	V179T	2	Inf
<b>V75L</b>	G190S	3.24	Inf	G190S	Y115F	1.5	2.62
M184V	V106M	3	Inf	G190S	V179D	1.5	2.62
G190S	<b>V75L</b>	2.5	4.03	Y181C	K65R	1.5	8.8
<b>L228R</b>	G190S	2.25	Inf	G190S	<b>L228R</b>	1.33	3.74
G190S	V179T	2	Inf	M184V	<b>V75L</b>	1.25	4.03
G190S	V179E	2	Inf	K65R	V106M	1.2	Inf
K65R	<b>V75L</b>	2	5.04	Y115F	G190S	1.05	Inf

Boldface mutations have not been commented so far. **Inf**: Infinity. Mut 1/2: mutation 1/2. Because the co-variation based on conditional selection pressure is directional, mutation 1 is the dominant mutation and mutation 2 is the affected mutation.


## Figures



**Fig.1.** Natural polymorphisms in CRF01\_AE HIV-1.

**Figure 1**


Natural polymorphisms in HIV-1 CRF01\_AE. Positions are shown along the x-axis, and the mutation frequency for each subtype or lineage is shown along the y-axis. Sites associated with drug resistance in subtype B are boxed. Bar colors denote statistical significance: black is statistically significant ( $|Z| \geq 3$ ); gray is borderline statistically significant ( $1 \leq |Z| < 3$ ); white is not statistically significant ( $|Z| < 1$ ). The difference between CRF01\_AE lineages 1 and 2 is marked with \*, marked on the higher bars in lineage 1 or 2, respectively.



**Fig.2.** Natural polymorphisms compared between CRF01\_AE-infected patients who experienced antiretroviral treatment (ART) failure and success.

## Figure 2

Natural polymorphisms compared between CRF01\_AE-infected patients who experienced antiretroviral treatment (ART) failure and success. Positions are shown along the x-axis, and the mutation frequency for each group is shown along the y-axis. Sites associated with drug resistance in subtype B are boxed. Bar colors denote statistical significance: black is statistically significant ( $|Z \text{ value}| \geq 3$ ); gray is borderline statistically significant ( $1 \leq |Z \text{ value}| < 3$ ); white is not statistically significant ( $|Z \text{ value}| < 1$ ).



**Fig.3.** Temporal association of Y181C and L228R in CRF01\_AE-infected individuals during antiretroviral treatment (ART).

### Figure 3

Temporal association of Y181C and L228R in CRF01\_AE-infected individuals during antiretroviral treatment (ART). 301426, 301507, and 302181 were three CRF01\_AE-infected individuals in which both Y181C and L228R mutations were detected at treatment failure (TF). Longitudinal plasma samples were studied using deep sequencing of the pol-RT sequences. Black circle represents the percentage of Y181C quasispecies; black square represents the percentage of L228R quasispecies.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile3.pdf](#)
- [Additionalfile2.pdf](#)